E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of HIV-1 infection |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of HIV-1 infection |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10068341 |
E.1.2 | Term | HIV-1 infection |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To evaluate the efficacy of oral ISL QM compared to FTC/TDF QD for the prevention of HIV-1 infection as assessed by the incidence rate per year of confirmed HIV-1 infections 2. To evaluate the safety and tolerability of oral ISL QM compared to oral FTC/TDF QD as assessed by review of the accumulated safety data
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of oral ISL QM in reducing the incidence per year of HIV-1 infection relative to the background rate |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results before randomization. 2. Has been sexually active (vaginal and/or anal sex) with a male sexual partner in the 30 days prior to Screening. 3. Is at high risk for HIV-1 infection as defined by a risk score ≥5 using a VOICE risk score tool (sites in Africa) or meets the CDC criteria for PrEP eligibility (sites in the US). 4. Was assigned female sex at birth, is cisgender, 16 years to 45 years of age, inclusive, at the time of providing informed consent/assent. 5. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: • Is not a WOCBP OR • Is a WOCBP and using an acceptable contraceptive method, during the intervention period and for at least 42 days after the last dose (corresponding to the time needed to eliminate any study intervention [approximately 5 terminal halflives]). • A WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) within 24 hours before the first dose of study intervention. • If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. 6. The participant (or legally acceptable representative) has provided documented informed consent/assent for the study. 7. Has no plans to relocate or travel away from the site for ≥4 consecutive weeks during study participation.
|
|
E.4 | Principal exclusion criteria |
1. Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator. 2. Findings of chronic HBV (HBsAg-positive) or past HBV (HBsAg-negative and HBcAb-positive) infection, which could indicate risk for hepatitis B reactivation. 3. Current or chronic history of liver disease (eg, nonalcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert’s syndrome, asymptomatic gallstones, or cholecystectomy), unless the participant has stable liver function tests and no significant hepatic synthetic dysfunction. 4. Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer. 5. Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to enroll. 6. Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time (past or current use). 7. Is currently receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the duration of the study. 8. Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 30 days prior to Day 1 through the duration of the study. 9. Has exclusionary laboratory values within 45 days prior to Day 1. 10. Is expecting to conceive or donate eggs at any time during the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Incidence Rate Per Year of Confirmed HIV-1 Infections 2. Percentage of Participants Who Experienced One or More Adverse Events 3. Percentage of Participants Who Discontinued Treatment Due to an Adverse Event
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Up to approximately 36 months 2. Up to approximately 37 months 3. Up to approximately 36 months
|
|
E.5.2 | Secondary end point(s) |
Incidence Rate per Year of Confirmed HIV-1 Infections Among Participants |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Up to approximately 36 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Kenya |
Malawi |
South Africa |
Eswatini |
Uganda |
United States |
Zambia |
Zimbabwe |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 3 |